Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study

被引：0
|
作者：
Gruenig, Ekkehard [1 ]
Galie, Nazzareno [2 ]
Humbert, Marc [3 ,4 ,5 ]
Keogh, Anne M. [6 ]
Langleben, David [7 ]
Rubin, Lewis J. [8 ]
Speich, Rudolf [9 ]
Fritsch, Arno [10 ]
Davie, Neil [10 ]
Ghofrani, Hossein-Ardeschir [11 ,12 ]
机构：
[1] Univ Heidelberg Hosp, Thoraxclin, Thoraxclin Heidelberg, Ctr Pulm Hypertens, Heidelberg, Germany
[2] Univ Bologna, Inst Cardiol, Bologna, Italy
[3] Univ Paris 11, Le Kremlin Bicetre, France
[4] INSERM, F-94275 Le Kremlin Bicetre, France
[5] Hop Bicetre, AP HP, Serv Pneumol, Le Kremlin Bicetre, France
[6] St Vincents Hosp, Heart Lung Transplant Unit, Sydney, NSW 2010, Australia
[7] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Pulm Vasc Dis, Montreal, PQ H3T 1E2, Canada
[8] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[9] Univ Zurich Hosp, Dept Internal Med, Zurich, Switzerland
[10] Bayer HealthCare Pharmaceut, Global Clin Dev, Wuppertal, Germany
[11] Univ Giessen, Dept Internal Med, Giessen, Germany
[12] Marburg Lung Ctr UGMLC, Giessen, Germany
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
Pulmonary hypertension; Treatments; Nitric oxide;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2347
引用
收藏
页数：2
相关论文
共 50 条
  • [1] RIOCIGUAT FOR THE TREATMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): RESPONDER ANALYSIS OF WHO FUNCTIONAL CLASS II PATIENTS FROM THE PATENT-1 STUDY
    E, Gruenig
    Sikirica, M.
    Curram, J.
    Davie, N.
    Ghofrani, H. A.
    VALUE IN HEALTH, 2013, 16 (07) : A513 - A513
  • [2] Efficacy Of Riociguat In Pretreated Versus Treatment-Naive Patients With Pulmonary Arterial Hypertension (pah) In The Phase Iii Patent-1 Study
    Humbert, M. J. C.
    Galie, N.
    Ghofrani, H. A.
    Jansa, P.
    Keogh, A. M.
    Langleben, D.
    Meyer, G.
    Rubin, L. J.
    Torbicki, A.
    Wang, C.
    Fritsch, A.
    Neuser, D.
    Grimminger, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [3] Riociguat Treatment For Porto-Pulmonary Hypertension: A Subgroup Analysis From The Patent-1 Study
    Cartin-Ceba, R.
    Halank, M.
    Ghofrani, H-A.
    Humbert, M.
    Mattson, J.
    Fritsch, A.
    Krowka, M. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [4] Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1
    Preston, Ioana
    Al-Naamani, Nadine
    Ghio, Stefano
    Ghofrani, Hossein-Ardeschir
    Hassoun, Paul
    Nikkho, Sylvia
    Fritsch, Arno
    Torbicki, Adam
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [5] Comparison of hemodynamic parameters in treatment-naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT-1 study
    Jing, Z. -C.
    Galie, N.
    Ghofrani, H. -A.
    Humbert, M.
    Langleben, D.
    Rubin, L. J.
    Hoeper, M. M.
    Fritsch, A.
    Davie, N.
    Keogh, A. M.
    EUROPEAN HEART JOURNAL, 2013, 34 : 45 - 46
  • [6] Baseline Characteristics And Response To Treatment In Pretreated Versus Treatment-Naive Patients With Pulmonary Arterial Hypertension (pah) In The Phase Iii Patent-1 Study
    Langleben, D.
    Galie, N.
    He, J.
    Huang, Y.
    Humbert, M.
    Keogh, A. M.
    Kilpatrick, D.
    Rubin, L. J.
    Zhou, D.
    Fritsch, A.
    Neuser, D.
    Ghofrani, H. -A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [7] Riociguat For The Treatment Of Pulmonary Arterial Hypertension (pah): A Phase Iii Long-Term Extension Study (patent-2)
    Rubin, L. J.
    Galie, N.
    Grimminger, F.
    Grunig, E.
    Humbert, M. J. C.
    Jing, Z. -C.
    Keogh, A. M.
    Langleben, D.
    Fritsch, A.
    Kilama, M. Ochan
    Neuser, D.
    Ghofrani, H. -A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [8] Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
    Humbert, Marc
    Coghlan, J. Gerry
    Ghofrani, Hossein-Ardeschir
    Grimminger, Friedrich
    He, Jian-Guo
    Riemekasten, Gabriela
    Vizza, Carmine Dario
    Boeckenhoff, Annette
    Meier, Christian
    Pena, Janethe de Oliveira
    Denton, Christopher P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 422 - 426
  • [9] Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
    Cartin-Ceba, Rodrigo
    Halank, Michael
    Ghofrani, Hossein-Ardeschir
    Humbert, Marc
    Mattson, John
    Fritsch, Arno
    Krowka, Michael J.
    PULMONARY CIRCULATION, 2018, 8 (02)
  • [10] EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (CTD): RESULTS FROM PATENT-1 AND PATENT-2
    Denton, C.
    Coghlan, J. G.
    Ghofrani, H. -A.
    Grimminger, F.
    He, J.
    Riemekasten, G.
    Vizza, C. D.
    Boeckenhoff, A.
    Meier, C.
    Nikkho, S.
    Pena, J.
    Humbert, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 588 - 589
12345